Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Centre for Commercialization of Cancer Immunotherapy - C3i

$15 million for 2016-21
logo

Headquarters
Montréal, Quebec

Chief Medical Officer
Lambert Busque Lambert Busque

Board chair
Louis Lacasse Louis Lacasse

Accelerating the immunotherapy cancer care revolution


The opportunity

Immunotherapy is a rapidly emerging practice that harnesses the power of the immune system to combat cancer. It could revolutionize cancer care by developing nontoxic, highly efficient and decisive cures that do not rely on chemotherapeutic agents, thus improving patients’ quality of life and reducing healthcare costs. These treatments could be used in 60% of advanced cancer patients by 2025. Canada needs greater capacity to translate these therapies into patient care, and to help Canadian companies compete in a potential $40 billion market.

How C3I is seizing the opportunity

The Centre for Commercialization of Cancer Immunotherapy (C3i) will accelerate access to innovative cancer immunotherapies for patients. Operating out of the Hôpital Maisonneuve-Rosemont installation of the Integrated University Center of East Montreal (CIUSS de l’Est-de-l’île-de-Montréal), the centre will offer an integrated structure for the development, translation and commercialization of these groundbreaking therapies. C3i will combine three interacting units that will provide patients with cutting edge biomarker and diagnostics tests, good manufacturing practices standards and rapid access to clinical trials and regulatory support to bring effective and affordable remedies more rapidly to Canadians and the world. This will strengthen Canada’s position as a leader in the emerging field of cancer immunotherapy.

Among the expected results

  • C3I will work to reverse the erosion of Canada’s competitiveness in global pharmaceutical markets. The centre will incorporate Canadian and foreign investments to reboot clinical trial development and enhance collaborative activities with Canadian subsidiaries of major pharmaceutical companies.
  • By bringing together specialized laboratories, a unique Good Manufacturing Process facility, extensive research and entrepreneurial expertise, and a large patient base, C3i will make it easier for Canadian health professionals and patients to gain early access to promising therapies at the developmental stage.
  • Key partnerships between C3i and pharmaceutical companies have paved the way for the first clinical trials in Canada using various cutting edge technologies based on cellular therapy including CAR-T cells (immunity cells engineered to target cancer).